Targets › RET
17 programs from 15 companies in 47 trials: 23 Phase 2, 14 Phase 1, 7 Phase 3, 3 Phase 4; Oncology, Gastroenterology; next expected readout Nov 2026.
Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15). In contrast to most receptor tyrosine kinases, RET requires not only its cognate ligands but also coreceptors, for activation. (UniProt, P07949)
Open in Phaseline: the race on RET, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals | Pralsetinib Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor | RET, CCDC6, KIF5B | Phase 4 | NSCLC (Non-small Cell Lung Cancer) | Jul 2027 |
| Chia Tai Tianqing Pharmaceutical Group | AL2846 Capsule Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET | MET, KIT, FLT4, RET | Phase 3 | Thyroid Cancer | Jan 2027 |
| Roche | Alectinib ALK tyrosine kinase receptor inhibitor; Tyrosine-protein kinase receptor RET inhibitor; EML4-ALK inhibitor | ALK, RET, EML4 | Phase 3 | Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Solid Tumors; ALK Fusion-positive Solid or CNS Tumors … | Jan 2027 |
| Eli Lilly | Selpercatinib Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor | RET, KIF5B, CCDC6 | Phase 3 | Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Solid Tumor; Medullary Thyroid Cancer … | Feb 2027 |
| Eli Lilly | Selpercatinib (LY3527723) Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor | RET, KIF5B, CCDC6 | Phase 3 | Medullary Thyroid Cancer | Nov 2027 |
| Shouyao Holdings (Beijing) Co. LTD | SY-5007 RET inhibitor | RET | Phase 3 | Non-Small Cell Lung Cancer | – |
| Jiangxi Provincial Cancer Hospital | Anlotinib hydrochloride Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, RET, KIT) | VEGFR, FGFR, RET, KIT | Phase 2 | Esophageal Squamous Cell Carcinoma | Nov 2026 |
| Roche | Pralsetinib Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor | RET, CCDC6, KIF5B | Phase 2 | Non-small Cell Lung Cancer; Advanced Thyroid Cancer Patients Who Received Target Therapy; Lung Cancer Stage III | Nov 2026 |
| Beijing Scitech-Mq Pharmaceuticals | ST-1898 Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI | VEGFR2, MET, AXL, PDGFRA, RET | Phase 2 | Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell Carcinoma | Dec 2026 |
| Nanfang Hospital, Southern Medical University | Donafenib multi-targeted tyrosine kinase inhibitor | BRAF, FLT3, RET | Phase 2 | Unresectable Hepatocellular Carcinoma | Dec 2026 |
| Fudan University | Sitravatinib Small molecule inhibitor of receptor tyrosine kinases | PDGFRA, KIT, RET, FLT3 | Phase 2 | Metastatic Breast Cancer | Jun 2027 |
| Jiangsu Hansoh Pharmaceutical | HS-10365 RET inhibitor | RET | Phase 2 | Nonsmall Cell Lung Cancer | Aug 2027 |
| Eye & ENT Hospital of Fudan University | Anlotinib Hydrochloride Multi-target tyrosine kinase inhibitor | VEGFR, FGFR, RET, KIT | Phase 2 | Adenoid Cystic Carcinoma | Jun 2028 |
| Sichuan Kelun-Biotech Biopharmaceutical | KL590586 RET inhibitor | RET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Ellipses Pharma | EP0031 (Lunbotinib) RET inhibitor | RET | Phase 1 | NSCLC | Mar 2027 |
| Taiho Pharmaceutical | TAS0953/HM06 RET inhibitor | RET | Phase 1 | RET-altered Non Small Cell Lung Cancer | Mar 2030 |
| Applied Pharmaceutical Science | APS03118 RET inhibitor | RET | Phase 1 | RET-altered Solid Tumors | – |
Non-Small Cell Lung Cancer (5) Carcinoma, Non-Small-Cell Lung (2) Haematological Malignancy (2) Non-small Cell Lung Cancer (2) Medullary Thyroid Cancer (2) Differentiated Thyroid Carcinoma (1) Unresectable or Metastatic Melanoma (1) Advanced Renal Cell Carcinoma (1) Solid Tumors (1) ALK Fusion-positive Solid or CNS Tumors (1) Drug Monitoring (1) Advanced Cancer (1)
small molecule (14), mixed (2), antibody (1)
Roche (2) Eli Lilly (2) Beijing Scitech-Mq Pharmaceuticals (1) Ellipses Pharma (1) Fudan University (1) Taiho Pharmaceutical (1) Jiangxi Provincial Cancer Hospital (1) Nanfang Hospital, Southern Medical University (1) Jiangsu Hansoh Pharmaceutical (1) Shouyao Holdings (Beijing) Co. LTD (1) Rigel Pharmaceuticals (1) Eye & ENT Hospital of Fudan University (1) Chia Tai Tianqing Pharmaceutical Group (1) Applied Pharmaceutical Science (1) Sichuan Kelun-Biotech Biopharmaceutical (1)
KIT (4) CCDC6 (4) KIF5B (4) MET (2) PDGFRA (2) FLT3 (2) VEGFR (2) FGFR (2) VEGFR2 (1) AXL (1) ALK (1) EML4 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.